Table 2. Ongoing clinical trials for potential vaccines against Sars-CoV-2.
| Vaccine prospect | Developer | Technology | Evolution of trial | ||
|---|---|---|---|---|---|
| Phase | Number of Participants | Duration (MM/YY) | |||
| NVX-CoV2373 50 | Novavax | recombinant spike protein | I | 131 | 05/20 - 07/21 |
| SCB-2019 51 | Clover Biopharm | spike protein trimeric subunit | I | 150 | 06/20 - 03/21 |
| AG0301-COVID19 52 | AnGes Inc. | DNA plasmid | I - II | 30 | 06/20 - 07/21 |
| Ad5-nCoV 53 | CanSinoBiologics | recombinant adenovirus vector | II | 382 | 03/20 - 12/20 |
| AZD1222 54 | Univ. Of Oxford | adenovirus vector | II - III | 10 260 | 05/20 - 08/21 |
| BNT162 55 | BioNTech | RNA | II - III | 30 000 | 04/20 - 05/21 |
| CoronaVac 56 | Sinovac Biotech | inactivated SARS-CoV-2 virus | III | 10 490 | 04/20 - 12/20 |
| BBIBP-CorV 57 | Sinopharm | inactivated SARS-CoV-2 virus | III | 15 000 | 07/20 - 07/21 |
| mRNA-1273 58 | Moderna | nanoparticle | III | 30 000 | 07/20 - 10/21 |